Skip to main navigation
Skip to search
Skip to main content
Icahn School of Medicine at Mount Sinai Home
Help & FAQ
Home
Profiles
Research units
Publications & Research Outputs
Press/Media
Search by expertise, name or affiliation
Antiinflammatory therapy with canakinumab for atherosclerotic disease
CANTOS Trial Group
Icahn School of Medicine at Mount Sinai
Medicine
Medicine - Cardiology
Research output
:
Contribution to journal
›
Article
›
peer-review
6477
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Antiinflammatory therapy with canakinumab for atherosclerotic disease'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Atherosclerotic Disease
100%
Anti-inflammatory Therapy
100%
Canakinumab
100%
Placebo
75%
Confidence Interval
62%
Hazard Ratio
37%
Lipid Levels
37%
Placebo Groups
25%
Interleukin-1β
25%
C-reactive Protein Level
25%
High-sensitivity C-reactive Protein (hs-CRP)
25%
Cardiovascular Risk
12%
Inflammation
12%
Cardiovascular Mortality
12%
Therapeutic Monoclonal Antibody
12%
All-cause Mortality
12%
No Significant Difference
12%
Hospitalization
12%
Antibody Targeting
12%
High Incidence
12%
Clinical Data
12%
Mortality Hazard
12%
Statistical Significance
12%
Low Dose Rate
12%
Revascularization
12%
Incidence Rate
12%
Previous Myocardial Infarction
12%
Nonfatal Myocardial Infarction
12%
Nonfatal Stroke
12%
Innate Immunity
12%
Recurrent Cardiovascular Events
12%
Stable Angina
12%
Atherothrombosis
12%
Fatal Infection
12%
Randomized Double-blind Trial
12%
Level Lowering
12%
Inflammatory Hypothesis
12%
Pharmacology, Toxicology and Pharmaceutical Science
Disease
100%
Placebo
100%
Canakinumab
100%
Heart Infarction
25%
C Reactive Protein
25%
Interleukin 1
25%
Inflammation
12%
All Cause Mortality
12%
Monoclonal Antibody
12%
Infection
12%
Thrombosis
12%
Cerebrovascular Accident
12%
Unstable Angina Pectoris
12%
Cardiovascular Disease
12%